Listen to the article
A new experimental weight-loss injection developed by Eli Lilly has shown impressive results in a recent clinical trial, helping participants lose up to 20% of their body weight over a 48-week period.
The drug, called eloralintide, is administered as a weekly injection and produced “meaningful, dose-dependent weight loss” in adults who were overweight or obese but did not have diabetes, according to researchers. In contrast, participants who received a placebo lost just 0.4% of their body weight during the same period.
The Phase 2 trial, funded by Eli Lilly, involved 263 adults and found that treatment with eloralintide was also associated with improvements in several key health markers. Participants saw reductions in waist circumference and blood pressure, along with better lipid profiles, glycemic control, and decreased inflammation markers—all factors that can contribute to cardiometabolic risk.
“The weight loss we saw in the study is clinically impactful,” said lead study author Dr. Liana K. Billings, director of clinical and genetics research in diabetes and cardiometabolic disease at Endeavor Health in Skokie, Illinois. “With this degree of weight loss in only 48 weeks, we see people having improvement or resolution in other conditions like hypertension, hyperlipidemia, osteoarthritis, sleep apnea and more weight-related conditions.”
Notably, researchers did not observe a plateau in weight loss during the study period, suggesting that participants might continue losing weight if treatment were extended. Dr. Billings also highlighted that up to 90% of participants taking eloralintide improved by at least one BMI category.
The findings were published in The Lancet and presented at ObesityWeek 2025 in Atlanta, Georgia, earlier this month.
Unlike popular GLP-1 medications such as Ozempic, Wegovy, Mounjaro, and Zepbound—which work by mimicking the gut hormone glucagon-like peptide-1—eloralintide operates through a different mechanism. It’s classified as a selective amylin receptor agonist, mimicking amylin, a hormone produced by the pancreas. Similar to GLP-1 drugs, it helps slow digestion, reduce appetite, and control blood sugar after meals.
The drug has not yet received FDA approval for clinical use. Eli Lilly plans to launch Phase 3 clinical studies for obesity treatment by the end of this year, according to company representatives. The pharmaceutical giant is also evaluating the drug’s potential use in combination with GLP-1 medications.
The most common side effects reported during the trial were mild to moderate gastrointestinal symptoms and fatigue, with these effects being more pronounced at higher doses. The researchers noted that the medication was generally well-tolerated by study participants.
Dr. Billings emphasized the need for diverse treatment options in addressing obesity. “Obesity is a complex condition, and no single treatment works for everyone,” she said. “To truly address each patient’s needs, we need therapies with different mechanisms of action so that each person can receive the treatment that offers the best balance of effectiveness and tolerability for them.”
Some medical professionals have expressed mixed views about the proliferation of weight-loss medications. Dr. Brett Osborn, a Florida neurosurgeon and longevity expert not involved in the study, raised concerns about the pharmaceutical industry’s continued development of new anti-obesity drugs.
“Between all the agents out there, there is no way any person cannot lose weight when coupled with progressive resistance training and attention to their daily macronutrient intake, even if only a little,” Dr. Osborn said. He noted that the reduced cardiovascular risk observed in the study was likely attributable to participants losing body fat, which generally decreases the risk for age-related diseases.
Dr. Sue Decotiis, a medical weight-loss specialist in New York City, suggested that targeting multiple receptor systems may lead to greater weight loss. “It seems that the more receptor systems that are influenced, the more weight a patient can lose,” she explained. “This is why tirzepatide (Mounjaro, Zepbound), which hits two receptors, induced more weight loss than Ozempic and Wegovy.”
Safety advocates urge caution regarding potential long-term effects. “Some side effects are rare or take time to show up, so it is important to monitor new drugs like eloralintide for safety over the long term,” said Whitney Di Bona, an attorney and consumer safety advocate for Drugwatch. “Even with careful studies, some risks may only become clear after the drug is used by many people.”
Fact Checker
Verify the accuracy of this article using The Disinformation Commission analysis and real-time sources.
11 Comments
Interesting to see this new weight-loss injection showing promising results. I wonder how it compares to other emerging treatments and what the long-term safety profile looks like. Definitely an area worth watching for further developments.
I agree, the weight loss achieved in the trial sounds quite significant. But with any new drug, it’s crucial to thoroughly evaluate the risks and benefits before approving for wider use.
Exciting development, but the caution from experts is warranted. Meaningful weight loss is important, but not if it comes with serious side effects. I’ll be watching closely as this drug progresses through further trials.
This could be a game-changer for obesity treatment if the benefits are sustained. But the potential risks are concerning, and I hope regulators take a very measured approach to approving it. Weight loss is crucial, but not at the expense of safety.
Well said. Obesity is such a major health crisis, but rushing unsafe or poorly-tested drugs to market would be a mistake. Responsible development and evaluation should be the top priority.
A 20% body weight reduction in just 48 weeks is quite impressive, if these results hold up. The improvements in cardiometabolic markers are also noteworthy. However, I share the experts’ caution – the long-term effects need very careful study.
Absolutely, new drug therapies can have unexpected side effects that only become apparent with wider and longer-term use. Rigorous clinical trials and post-approval monitoring will be essential.
I’m curious to learn more about how this injection works and what the proposed mechanism of action is. The cardiometabolic benefits are intriguing, but understanding the full risk profile will be key.
Good point. The drug’s precise mechanism and impact on various bodily systems needs to be thoroughly investigated. Safety has to be the top priority, even for an obesity treatment with promising initial results.
Obesity is such a serious, widespread health issue, so new treatment options are needed. But this injection will have to prove its safety and efficacy through rigorous further study before it can be responsibly brought to market.
20% weight loss in less than a year is a remarkable outcome, if it can be replicated. But the experts are right to urge caution. Ensuring long-term safety should be the highest concern before any approvals.